Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (NCT04304820), a non-randomized phase 2 study. The primary outcome is Number of Participants Meeting Safety and Feasibility Criteria During Study Treatment Period With Oral Treatment (Low Dose Cyclosporine and Eltrombopag) Until the Start of Standard of Care Treatment (Horse Anti-thymocyte-globulin).

2. Clinical Question

The question is about whether participants can proceed through an early oral-treatment period while meeting the registry-defined criteria. Feasibility is not simply a measure of whether a participant takes medication: the composite also includes TRSAE, mis- and altered diagnosis, and failure to establish care at the National Institutes of Health Clinical Center. The record does not define TRSAE further.

This is a descriptive question within a single-group study, not a randomized comparison of early oral treatment against another assigned strategy. Without a concurrent control group, the design cannot isolate how outcomes would differ under an alternative treatment pathway. The registry record does not report a primary endpoint result, so the available information does not establish how many participants met the composite criteria.

3. Trial Design

This is a phase 2, non-randomized, single-group study with no masking. Its listed enrollment is 80, and its status is recruiting. The recorded start date is 2020-05-07, and the primary completion date is 2024-12-18. Those dates and the enrollment entry describe the registry record; they do not establish that recruitment or follow-up is complete.

The study concerns treatment-naïve participants with severe aplastic anemia. The brief summary describes starting oral cyclosporine and eltrombopag before horse anti-thymocyte globulin. Participants may receive horse anti-thymocyte globulin at the Clinical Center. The record therefore describes an early oral-treatment period leading up to standard-of-care treatment, rather than a randomized assignment between two complete treatment strategies.

Screening is described as including medical history, physical examination, electrocardiogram, blood tests, family history, bone marrow biopsy, and review of current medicines. Some screening may take place remotely. The registry summary also describes weekly telephone calls for participants who start treatment at home before visiting the Clinical Center. These are descriptions of study procedures, not evidence about outcomes.

The primary outcome is a participant count for a composite of safety and feasibility criteria, assessed over up to 12 weeks from oral-treatment initiation. Secondary outcomes include hematological response, relapse, clonal evolution, overall survival, response after restarting cyclosporine and/or eltrombopag, and freedom from horse anti-thymocyte globulin. The registry record lists 7 outcome measures and 0 analyses. It does not report a primary endpoint result or a statistical analysis plan.

Because allocation is non-randomized and the model is single-group, there is no randomized control comparison. This limits causal interpretation: outcomes during the study cannot be directly contrasted with outcomes under an alternative assigned regimen. The lack of masking also means treatment and outcome assessment are not described as blinded. The record does not report whether any outcome assessors were masked separately.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: analysis was intention-to-treat

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants Meeting Safety and Feasibility Criteria During Study Treatment Period With Oral Treatment (Low Dose Cyclosporine and Eltrombopag) Until the Start of Standard of Care Treatment (Horse Anti-thymocyte-globulin), measured over Up to 12 Weeks from the initiation of oral treatment (Low Dose Cyclosporine and Eltrombopag).

The primary endpoint counts participants meeting the study’s safety and feasibility criteria during the study-treatment period. That period begins when low-dose oral cyclosporine and eltrombopag are initiated and ends when standard-of-care horse anti-thymocyte globulin starts. The timeframe is up to 12 weeks from oral-treatment initiation.

The registry defines the composite using TRSAE, mis- and altered diagnosis, non-compliance with the regimen, or failure to establish care at the National Institutes of Health Clinical Center. The record does not explain the acronym TRSAE or give further operational detail about how the criteria are assessed. It also does not report the number meeting the endpoint.

A composite endpoint can capture several distinct events in one measure. In general, this can be useful when a study’s question concerns more than one way a treatment period might become unsafe or infeasible. However, a combined count does not by itself show which component contributed most, and components may differ in clinical meaning. Component-level counts would be needed to describe their separate contributions; those counts are not reported in the registry record.

The endpoint is appropriate to the stated safety-and-feasibility question, but it is not itself a direct measure of hematological response or long-term disease control. Those topics appear among the secondary outcomes. Since no primary endpoint result is reported, the registry information does not show the observed composite count or its precision.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical interpretation depends on the study design, the definition of the outcome, the analysis population, and the information available about uncertainty. In general, a statistical method should be read in light of the question it can answer, rather than as a stand-alone label. For this study, the registry record describes a single-group, non-randomized phase 2 design and a participant-count primary endpoint. It does not report a statistical analysis plan or a primary endpoint analysis.

What does a single-group design estimate?

In general, a single-group study describes outcomes among participants who receive the study regimen. For a binary participant-level outcome, the observed count and the number assessed can be used to estimate the proportion meeting the outcome. A confidence interval, when reported, conveys the range of values reasonably compatible with the observed data under the assumptions of the method. It does not eliminate bias from participant selection, outcome measurement, or other differences that could influence the result.

Because this study is non-randomized and single-group, it does not estimate a randomized treatment contrast. There is no assigned control group against which to compare the primary endpoint. A comparison with an external or historical group would require details about how that group was selected and how differences were handled; such a comparison is not reported in the registry record.

How should a participant count be read?

The primary endpoint is defined as a count of participants meeting a composite criterion. In general, a count is most interpretable when accompanied by the relevant analysis denominator, the assessment period, and a clear account of missing or unevaluable outcomes. If the aim is to express a participant count as a proportion, the denominator must match the population and period being analyzed. The registry record does not report the primary endpoint count, its denominator, or an uncertainty interval.

Participant counts also differ from event counts. One participant may experience more than one event, while a participant-level composite generally records whether the participant met the criterion. The endpoint description frames the primary measure as a participant count; it does not report component-level results or explain how repeated events are handled. The serious-adverse-event summary separately reports affected participants and participants at risk, so those figures should not be treated as a count of all event episodes.

What does an intention-to-treat population mean?

The primary endpoint description says the analysis was intention-to-treat. In general, an intention-to-treat approach aims to analyze participants according to their original study assignment, regardless of later adherence or treatment changes. In a single-group study there is no randomized assignment between arms, so the exact operational meaning still depends on how the registry defines the analysis set. The record does not report eligibility rules for inclusion in the primary analysis, handling of participants who do not start treatment, or how missing outcome information is treated.

How should uncertainty be understood?

In general, a confidence interval communicates statistical uncertainty around an estimate under specified assumptions. A narrow interval indicates greater precision than a wide interval, but precision is not the same as freedom from bias. A p-value, when used, addresses compatibility of the observed data with a specified null hypothesis under the analysis assumptions; it does not establish clinical importance or prove a cause-and-effect relationship. No confidence interval, p-value, or primary endpoint estimate is reported in the registry record.

The registry record lists 0 analyses. It does not state which statistical tests or models would be used for the primary or secondary outcomes, whether adjustment for covariates was planned, or how repeated observations would be handled. Those elements should not be inferred from the phase label or the endpoint descriptions.

What is the role of planning illustrations?

In general, a sample-size illustration is a planning calculation based on assumptions about the effect to detect, significance level, allocation, and statistical method. It is not an observed trial result and should not be described as observed power. The record’s stated illustration assumptions include a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the target effect expressed as a fraction of the observed effect. Such assumptions describe a hypothetical planning exercise, not the design of this single-group trial. No numerical planning results are reported in the registry record, and the record does not report its own sample-size justification.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Participants With Severe Aplastic Anemia in Early ")
n      <- c(39)
events <- c(37)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Participants With Severe Aplastic Anemia in Early   39  37  94.9  82.7  99.4  83.1  98.6  83.1  98.4

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists multiple outcomes, including the primary safety-and-feasibility measure and secondary measures of hematological response, relapse, clonal evolution, overall survival, response after restarting treatment, and freedom from horse anti-thymocyte globulin. When several outcomes or several statistical tests are considered, the chance of at least one apparently notable finding can increase. In general, multiplicity procedures can control that risk, but the appropriate approach depends on the study’s objectives and analysis plan.

The record does not report whether outcomes were tested in a hierarchy, whether any adjustment for multiple comparisons was planned, or which outcomes would be considered confirmatory. It lists 0 analyses, so no inferential results or multiplicity adjustments are reported. The outcome list alone does not show that every listed measure was formally tested.

Missing-data handling is also important. In general, incomplete follow-up can affect a participant count or proportion if participants with unknown outcome status differ from those with observed status. A clear report would identify the analysis denominator, describe missingness, and state how incomplete outcomes were handled. The registry record does not report missing-data methods or the number of participants with missing primary endpoint information.

The primary endpoint description identifies the analysis population as intention-to-treat, but the record does not specify how that population was operationalized in this single-group design. It also does not describe exclusions, treatment discontinuations, or sensitivity analyses. Without these details and the endpoint results, readers cannot assess the influence of missing information or alternative analysis choices.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: febrile neutropenia (7.7%), enterocolitis (7.7%), sepsis (7.7%), pancreatitis (5.1%), vomiting (5.1%).

The registry safety summary reports 24 participants with serious adverse events among 39 at risk, 39 participants with other adverse events among 39 at risk, and 1 death. These are distinct safety summaries; they should not be added together to create a total, because the record does not say whether participants overlap across categories. The figures are counts of participants, not necessarily counts of individual event episodes.

The listed serious-event terms include febrile neutropenia, enterocolitis, and sepsis, each reported as 7.7%, and pancreatitis, vomiting, and cholecystitis, each reported as 5.1%. These percentages describe the listed terms in the registry safety summary. The record does not explain whether a participant could contribute to more than one term, nor does it provide event timing or detailed attribution.

These safety entries should be read descriptively. They do not establish that an event was caused by cyclosporine, eltrombopag, horse anti-thymocyte globulin, or the study pathway as a whole. The non-randomized, single-group design provides no randomized safety comparison. The registry record does not report a causal analysis or additional detail on event adjudication.

13. What the Result Does, and Does Not, Mean

The record establishes that this study is designed to examine early oral cyclosporine and eltrombopag in treatment-naïve severe aplastic anemia, with a primary focus on a composite of safety and feasibility before horse anti-thymocyte globulin begins. It also documents a single-group, non-randomized phase 2 design and lists secondary outcomes related to response, relapse, clonal evolution, survival, retreatment response, and freedom from horse anti-thymocyte globulin.

It does not establish the observed primary endpoint result. The registry record lists 0 analyses and does not report how many participants met the safety-and-feasibility criteria, the denominator for that endpoint, or an interval describing its precision. The listed outcome names are not findings, and no result for the secondary outcomes is reported in the registry record.

The safety summary reports serious and other adverse-event participant counts and a death. These are important descriptive entries, but they do not by themselves identify the cause of events or provide a comparison with another treatment strategy. In general, an event occurring during a study does not automatically show that the study treatment caused it. The record does not report causal attribution or a randomized comparator.

Likewise, the study design cannot establish how outcomes would have differed under an alternative assigned approach. Without randomization or a reported comparison group, observed outcomes are not a controlled estimate of treatment effect. The record also does not report the statistical analysis plan, missing-data procedures, or multiplicity handling. Accordingly, the available information describes the trial question, methods, and selected safety counts, but not a definitive estimate of efficacy or a comparative safety effect.

14. Why This Trial Matters Statistically

This trial is statistically notable because its primary question is not framed as a direct comparison of two randomized treatment arms. It asks whether participants meet a defined safety-and-feasibility composite during early oral treatment before horse anti-thymocyte globulin begins. That makes the outcome closely tied to the treatment pathway and its practical demands, including adherence and establishing care at the National Institutes of Health Clinical Center.

The endpoint also illustrates a common statistical trade-off in composite outcomes. Combining several criteria can produce a single summary relevant to the study’s overall feasibility question. At the same time, a composite can obscure which components are driving the result and whether those components have similar meaning. In this case, the registry record does not report component-specific endpoint results, so that distinction cannot be evaluated.

The single-group, non-randomized design is central to what the study can estimate. It can describe outcomes in the study population, but it does not directly estimate a randomized difference against an alternative strategy. This matters when readers distinguish descriptive evidence from comparative evidence. The registry record lists secondary outcomes that may address response and longer-term disease events, but no analyses or results are reported.

Finally, the safety summary demonstrates why counts need context: the numbers of participants at risk and affected, event categories, possible overlap, and causal attribution all shape interpretation. The record supplies some participant counts and percentages, but does not report all of these details. The statistical value of the study will depend not only on the outcome definitions but also on complete reporting of estimates, denominators, uncertainty, and analysis methods.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation for interpreting outcomes is that the registry record does not report a primary endpoint result, any analyses, or results for the listed secondary outcomes. Consequently, the central safety-and-feasibility question cannot be answered from the recorded results. The endpoint count, denominator, and precision are not reported in the registry record.

The design is non-randomized and single-group, with no like-for-like randomized control comparison. This limits assessment of comparative effects and makes causal interpretation difficult. The record also states that masking is none. It does not report whether any separate outcome assessment procedures were masked.

The composite primary endpoint includes several criteria, but the record does not define TRSAE further or report component-specific results. It does not describe how a participant meeting multiple criteria is counted, or how timing and repeat events are handled. Those details can affect interpretation of a composite participant count.

The record does not report the statistical analysis plan, missing-data methods, multiplicity procedures, confidence intervals, or p-values. Although the primary endpoint description identifies an intention-to-treat analysis population, the operational definition and handling of participants with incomplete outcome information are not reported.

The safety summary provides affected and at-risk participant counts and selected event-term percentages, but it does not report event attribution, timing, or potential overlap across terms. With the study listed as recruiting, the registry status also means the record should not be treated as a completed account of all planned study information. These limitations concern the information and design described in the registry record; they do not establish that the study itself has no additional analyses or reports elsewhere.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) — NCT04304820.
• Registry record last updated 2026-03-09; status last verified 2026-02.
• Results first posted 2026-01-09.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes NCT04304820 as a recruiting phase 2, non-randomized, single-group study with no masking. It lists enrollment of 80 and concerns treatment-naïve participants ages 3 and older with severe aplastic anemia. The study examines early oral cyclosporine and eltrombopag before horse anti-thymocyte globulin.

The primary endpoint is a participant count meeting a composite safety-and-feasibility definition during up to 12 weeks from oral-treatment initiation. The record lists 7 outcome measures and 0 analyses. It does not report the primary endpoint result, a statistical analysis plan, or results for the secondary outcomes. The safety summary lists 24 participants with serious adverse events among 39 at risk, 39 with other adverse events among 39 at risk, and 1 death. These are descriptive safety entries, not a randomized comparison or proof of causation.